MedTrace Logo

Genetic Liability in the Brain Morphology of Attention Deficit Hyperactivity Disorder

NCT00161161 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2005-12-30

No results posted yet for this study

Summary

Attention Deficit Hyperactivity Disorder (ADHD) is a heritable psychiatric disorder with onset in childhood. Twin and adoption studies indicate that additive genetic factors explain up to 80% of the variance underlying susceptibility. The siblings of children with ADHD have a three- to fivefold increased risk of having ADHD compared to the siblings of healthy control subjects, and the risk is even greater for monozygotic twins with 50-80% concordance compared with up to 33% in dizygotic twins). As full siblings share on average 50% of their genes, even the unaffected siblings of children with ADHD would be expected to share some of the genes involved in the disorder. The neuroanatomical substrate of ADHD is becoming increasingly better defined by a growing body of evidence from imaging studies. Evidence from neuroimaging studies suggests that this disorder is associated with reductions in brain volume up to 5% in these children. In this protocol we collected MRI-scans from boys with ADHD and their unaffected siblings, as well as control subjects. In addition, cheekswabs were later collected for DNA analysis.

Conditions

  • Attention Deficit Hyperactivity Disorder

Sponsors & Collaborators

  • The Dutch Brain Foundation

    collaborator OTHER

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Sarah Durston, Ph.D. · RMI of Neuroscience, UMC Utrecht

Eligibility

Min Age
7 Years
Max Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-10-31
Completion
2002-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00161161 on ClinicalTrials.gov